The polycomb group (PcG) proteins, particularly Bmi1, have an essential role in maintaining the self-renewing capacity of leukemic stem cells (LSCs). Although one of their major targets in LSCs is known to be the Ink4a/Arf tumor suppressor gene locus, the role of PcG proteins in the leukemic reprogramming of target cells into LSCs is not well characterized. In this study, Bmi1 À/À granulocyte/macrophage progenitors (GMPs) were transformed with the leukemic fusion gene MLL-AF9. Although Bmi1 was not essential to the immortalization of GMPs in vitro, Bmi1
Introduction
Polycomb-group (PcG) proteins are transcriptional repressors that function by modulating chromatin structure. They form chromatin-associated multiprotein complexes, polycomb repressive complex (PRC) 1 and PRC2. PcG proteins have been implicated in the maintenance of self-renewing stem cells. 1 Bmi1, one of the components of PRC1, is essential for the maintenance of the self-renewal capability of somatic stem cells including hematopoietic stem cells (HSCs), neural stem cells and hepatic stem/progenitor cells. [2] [3] [4] Correspondingly, enforced expression of Bmi1 in HSCs augments their self-renewal capability. 4 One of the major targets of Bmi1 is the Ink4a/Arf locus, encoding a cyclin-dependent kinase inhibitor, p16
Ink4a , and a tumor suppressor, p19
Arf .
p16
Ink4a and p19 Arf function as major regulators of the senescence pathway, and deletion of both Ink4a and Arf in Bmi1-deficient mice substantially restored the defective self-renewal capacity of HSCs. 6 Recent comprehensive genome-wide analyses demonstrated that PcG and trithorax-group (TrxG) proteins mark developmental regulator gene promoters with bivalent domains consisting of overlapping repressive and activating histone modifications to keep them poised for activation in embryonic stem cells. 7 We also reported that Bmi1 reinforces bivalent histone domains at key hematopoietic regulator gene promoters in multipotent hematopoietic stem and progenitor cells to maintain their multipotency. 8 Bmi1 has also been implicated in the maintenance of the proliferative capacity of leukemic stem cells (LSCs). 2 Co-expression of HoxA9 and Meis1, which can transform HSCs, induced leukemia from Bmi1-deficient fetal liver cells in primary recipient mice but failed to sustain a leukemic state in the second recipients. 2 These findings suggested that Bmi1 regulates the self-renewal of both HSCs and LSCs. Consistent with these findings, levels of BMI1 expression in the CD34 þ cell fraction have been reported to correlate well with the progression and prognosis of myelodysplastic syndrome and chronic and acute myelogenous leukemia. [9] [10] [11] Recently, several leukemic genes have been demonstrated to directly transform myeloid progenitor cells, which do not have self-renewal capacity. These include MLL fusion genes and MOZ-TIF2.
12,13
MLL-AF9 directly transforms committed myeloid progenitors into LSCs. During this leukemic transformation process, LSCs maintain the global identity of the progenitor from which they arose while reacquiring the capacity for self-renewal by activating a limited stem-cell-or self-renewalassociated signature.
14 As evident from these findings, the transformation of normal HSCs and progenitors into LSCs is a process of epigenetic reprogramming, which involves drastic changes in histone modifications and DNA methylation. PRC2 has recently been implicated in the establishment and maintenance of cancer stem cells (CSCs). PRC2 represses the expression of tumor suppressor genes, such as BMP receptor 1B (BMPR1B) in glioblastoma. 15 Genes CpG methylated in colon cancer, such as tumor suppressor genes, are reportedly pre-marked by PRC2-mediated H3K27me3 in stem/progenitor cells, cells of CSC origin. 16 By contrast, the role of PRC1 in CSCs has not been well characterized except for gene silencing of the Ink4a-Arf locus. To further understand the role of PRC1, particularly Bmi1, in LSCs, we took advantage of the direct transformation of Bmi1-deficient myeloid progenitor cells by MLL-AF9, a process in which committed myeloid progenitors reprogram their expression profiles and re-acquire self-renewal capacity. In this study, we present an essential role for Bmi1 in the leukemic reprogramming of myeloid progenitors into LSCs.
Materials and methods

Mice
Bmi1 þ /À mice and Ink4a-Arf À/À mice that had been backcrossed at least eight times onto a C57BL/6 (B6-Ly5.2) background were used. C57BL/6 (B6-Ly5.2) mice were purchased from Japan SLC (Shizuoka, Japan). Mice congenic for the Ly5 locus (B6-Ly5.1) were bred and maintained at Sankyo-Lab Service (Tsukuba, Japan). All experiments using mice received approval from The Chiba University Administrative Panel for Animal Care.
Purification of mouse granulocyte/macrophage progenitors and flow-cytometric analysis
FcgRII/III hi granulocyte/macrophage progenitors (GMPs) were purified from BM. Mononuclear cells were isolated on FicollPaque PLUS (GE Healthcare, Buckinghamshire, UK) and incubated with a mixture of biotin-conjugated monoclonal antibodies against IL-7Ra, Sca-1 and lineage markers including Gr-1, Ter-119, B220, CD4 and CD8a (e-Bioscience and BioLegend, San Diego, CA USA). The cells were further stained with fluorescein isothiocyanate-conjugated anti-CD34, phycoerythrin-conjugated anti-FcgRII/III and allophycocyanin (APC)-conjugated anti-c-Kit antibodies (e-Bioscience). Biotinylated antibodies were detected with streptavidin-APC-Cy7 (BD Biosciences, San Jose, CA, USA). Four-color analysis and sorting were performed on a desktop cell sorter JSAN (Bay Bioscience, Kobe, Japan), FACSAria II (BD Biosciences) or FACSCanto II (BD Biosciences).
Retroviral constructs and transduction
MLL-AF9 complementary DNA was subcloned into the retroviral vector pMXs-neo. 17 . GCDNsam Flag-Bmi1-IRES-EGFP has been described before. 4 To produce the recombinant retrovirus, plasmid DNA was transfected into PlatE packaging cells by CaPO 4 co-precipitation. Before transduction, GMPs were precultured for 24 h in IMDM with 20% fetal calf serum, 50 ng/ml SCF, 20 ng/ml Flt3L and 20 ng/ml chimeric protein of soluble-IL-6R and IL-6 (FP6, kindly provided by Kirin Pharma Co. Ltd, Gunma, Japan). Cells were then spinoculated with retroviral supernatant in the presence of protamine sulfate (10 mg/ml; Sigma, St Louis, MO, USA) for 30 min at 1350 g and 32 1C. Following the spinoculation, cells were further incubated for 24 h.
In vitro culture of MLL-AF9-transformed progenitors and transplantation
GMPs transduced with MLL-AF9 were plated in methylcellulose medium containing 50 ng/ml SCF, 10 ng/ml IL-6, 10 ng/ml GM-CSF, 10 ng/ml IL-3 and G418 (1 mg/ml). After 5 days of culture, colonies were counted and pooled, and then 1 Â 10 4 cells were replated in the same medium without puromycin. For growth assays, 1 Â 10 3 cells from the eighth round of culture were transferred to liquid culture in 96-to 48-well plates containing IMDM with 20% fetal calf serum, 20 ng/ml SCF, 20 ng/ml IL-6, 20 ng/ml GM-CSF and 20 ng/ml IL-3. The cultures were carried out in triplicate. The cells were counted at the indicated time points. Also, 4 Â 10 5 replated cells (B6-Ly5.2) were transplanted into lethally irradiated B6-Ly5.1 mice along with 2 Â 10 5 B6-Ly5.1 BM competitor cells (B6-Ly5.1). The chimerism of donor-derived hematopoiesis was monitored by flow cytometry. Peripheral blood cells were stained with a mixture of monoclonal antibodies that included phycoerythrinanti-Gr-1, phycoerythrin-anti-Mac-1, APC-anti-B220, APC-Cy7-anti-CD4, APC-Cy7-anti-CD8a, Pacific blue-anti-CD45.2 and phycoerythrin-Cy7-anti-CD45.1. The proportion of GFP-positive donor cells was evaluated by dividing the number of GFPpositive CD45.2-positive cells by the total number of CD45-positive cells (CD45.1 þ CD45.2). Peripheral blood white blood cell counts were made using an automated cell counter, Celltec a (Nihon Kohden, Tokyo, Japan). 
Homing assay
Microarray analysis
The c-Kit
GMPs immortalized by MLL-AF9 (designated herein as iGMPs) were purified by cell sorting. Total RNA was isolated using TRIzol LS Reagent (Invitrogen, Carlsbad, CA, USA) and its integrity was confirmed using LabChip RNA 6000 Nano chips and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Target cRNA was prepared from total RNA equivalent to 10 000 cells with a two-cycle complementary DNA synthesis kit and 3 0 -amplification reagents for IVT labeling (Affymetrix), and hybridized to a GeneChip Mouse Genome 430 2.0 oligonucleotide microarray (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. The expression value (Signal) and change value (Signal Log Ratio) of each gene were calculated and normalized using GeneChip Operating Software version 1.4 (Affymetrix). We performed the experiments in duplicate and selected the genes exhibiting a X2-fold change in all four comparisons.
Reverse-transcription PCR analysis
Total RNA was isolated using TRIZOL LS solution (Invitrogen) and reverse-transcribed by the ThermoScript RT-PCR system (Invitrogen) with an oligo-dT primer. Real-time quantitative PCR was performed with an ABI 7300/7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) using 
Western blotting and immunoprecipitation
The expression of Bmi1 in cells transformed with MLL-AF9 was detected by western blotting. Total cell lysate was resolved by sodium dodecyl sulfate-PAGE and transferred to a polyvinylidene difluoride membrane. The blots were probed with a mouse antiBmi1 antibody (229F6; Upstate Biotechnology, Lake Placid, NY, USA) and a horseradish peroxidase-conjugated secondary antibody. The protein bands were detected with an enhanced chemiluminescence reagent (SuperSignal, Pierce Biotechnology, Rockford, IL, USA).
Chromatin immunoprecipitation assay
Cells were fixed with 3% formaldehyde for 10 min and then incubated in the presence of 0.125 M. Glycine for 10 min. The cells were lysed with lysis buffer ((50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.1%sodium dodecyl sulfate, and a proteinase inhibitor cocktail (Complete Midi)) on ice for 20 min and sonicated. The lysate was separated into three samples diluted with an equal volume of dilution buffer (50 mM Tris-HCl (pH8.0), 150 mM NaCl, 1%Triton X-100, 0.1%sodium dodecyl sulfate, and a proteinase inhibitor cocktail (Complete Midi)). Immunoprecipitation was carried out using anti-Bmi1 (clone 8A9, kindly provided by Dr N Nozaki, MAB Institute Co. Ltd., Japan) and anti-monoubiquitinated H2A (H2Aub1) (E6C5, Millipore, Billerica, MA, USA) antibodies. For anti-H2Aub1, chromatin was immunoprecipitated overnight at 4 1C with antiH2Aub1, followed by the addition of anti-mouse IgMm (12-488, Millipore) and further incubation for 2 h at 4 1C. After the immunoprecipitation, 25 ml of salmon sperm DNA/Protein G and A sepharose beads was added and incubated for 1 h at 41C.
The immunoprecipitates were washed extensively and subjected to a Q-PCR analysis by SYBR Premix Ex Taq II (Takara, Tokyo, Japan) using the primers for the Tbx15 promoter region, sense primer 5 0 -GATGGCCAGCGCACAGCCTT-3 0 and antisense primer 5 0 -CAGCCCCCAGCCAATGGCAA-3 0 .
Results
Deletion of Bmi1 attenuates proliferation, but does not inhibit transformation of myeloid progenitors by MLL-AF9
Bmi1 is essential for the proliferative capacity of self-renewing HSCs. To determine whether Bmi1 also has a role in the proliferation of myeloid progenitor cells, we purified
þ FcgRII/III hi GMPs and cultured them in vitro. Bmi1
À/À GMPs exhibited a profoundly impaired proliferative capacity compared with the wild-type GMPs ( Figure 1) . As was the case in HSCs, 6 deletion of both Ink4a and Arf (Bmi1 À/À Ink4a-Arf À/À ) largely restored their proliferative capacity (Figure 1a) .
The leukemic fusion gene MLL-AF9 can directly transform GMPs into immortalized leukemic blast cells in vitro, and mice infused with these cells develop acute myeloid leukemia (AML), which harbors the GMP-like LSCs (L-GMPs). 14 We next asked whether Bmi1 has any impact on the proliferative capacity of transformed GMPs. We infected highly purified GMPs from wild-type, Bmi1
mice with an MLL-AF9 retrovirus and serially replated Ink4a-Arf À/À mice were infected with a MLL-AF9 retrovirus and serially replated in methylcellulose culture medium containing 50 ng/ml SCF, 10 ng/ml IL-6, 10 ng/ml GM-CSF, 10 ng/ml IL-3 and G418 (1 mg/ml). After 5 days of primary culture, colonies were counted and pooled, and then 1 Â À/À Ink4a-Arf À/À cells had a significantly smaller population with high levels of c-Kit, the expression of which directly reflects leukemogenic activity of MLL-AF9-transformed GMPs (Figure 2a) . 14 We next analyzed the expression of Ink4a and Arf in the purified c-Kit þ CD34 þ FcgRII/III hi LSC fraction from iGMPs at the fifth round of replating. De-repression of p16 Ink4a and p19
Arf mRNA expression was obvious in Bmi1 À/À cells compared with the wild-type iGMPs (Figure 2b ). These results indicated that Bmi1 is not essential for the transformation of myeloid progenitors by MLL-AF9 in vitro, but the absence of Bmi1 affects the proliferative capacity and immature state of the transformed cells.
Bmi1 is essential for the development of leukemia in vivo
It has been demonstrated that Bmi1 À/À fetal liver cells transformed by a Hoxa9-ires-Meis1 retrovirus induce AML in primary recipient mice, but cannot sustain leukemia in secondary recipients. 2 De-repression of negative regulator genes for stem cell maintenance, including Ink4a and Arf, was attributed to a loss of the self-renewal capacity of LSCs over time; however, this has not been tested by a genetic approach. 2 This model of leukemia using a Hoxa9-ires-Meis1 retrovirus targets self-renewing HSCs. 18 To understand the role of Bmi1 in the leukemic transformation of myeloid progenitors, a process in which myeloid progenitors reacquire the capacity for selfrenewal, we transplanted 4 Â 10 5 iGMPs at the fourth round of culture along with 2 Â 10 5 total BM radioprotective cells into lethally irradiated mice. By 90 days post-transplant, all the recipient mice transplanted with wild-type or Ink4a-Arf À/À iGMPs had died of AML, whereas mice transplanted with Bmi1 À/À iGMPs had not developed leukemia at all (Figure 3a) . Deletion of both Ink4a and Arf partially restored the leukemogenic activity of Bmi1 À/À iGMPs and B70% of the recipient mice developed AML, although with a significantly longer latency (Figure 3a) . Peripheral blood analysis revealed a very low repopulation capacity of Bmi1 À/À donor cells (Figure 3b ). Once leukemias were developed from Bmi1 À/À Ink4a-Arf
iGMPs, however, they showed very aggressive phenotypes similar to those from wild-type and Ink4a-Arf À/À iGMPs and all the mice infused with leukemic cells from primary recipients developed leukemia with a very short latency (Figure 3c) . To evaluate the capacity of Bmi1 À/À iGMPs to home to BM, 
CFSE-labeled wild-type and Bmi1
À/À iGMPs were transplanted into irradiated recipient mice. Bmi1 À/À iGMPs had a homing capacity comparable to the control iGMPs (Figure 3d ), suggesting that Bmi1 À/À iGMPs have a defect not in homing to BM but in proliferation in BM.
Bmi1 complementation does not confer full leukemogenic activity to Bmi1 À/À iGMPs
We previously reported that the complementation of Bmi1 À/À BM HSCs with Bmi1 restores their clonogenic activity in vitro and self-renewing capacity to repopulate the hematopoiesis of lethally irradiated recipient mice long term.
4.
We therefore transduced Bmi1 À/À Ink4a-Arf À/À iGMPs with a Bmi1 retrovirus and selected transduced cells by cell sorting using GFP as a marker antigen for transduction (designated as Bmi1 À/À Ink4a-Arf À/À /Bmi1 iGMPs). Western blot analysis revealed the expression of exogenous Bmi1 to be 10-fold higher than the level of endogenous Bmi1 in Ink4a-Arf À/À iGMPs (Figure 4a ). In contrast to Bmi1 À/À Ink4a-Arf À/À iGMPs, Bmi1 À/À Ink4a-Arf À/À /Bmi1 iGMPs showed a higher replating efficiency (Figure 4b ) and gave rise to compact colonies (Figure 4c) . Flow-cytometric analysis revealed that the Bmi1 À/À Ink4a-Arf À/À /Bmi1 iGMPs re-acquired a high level of c-Kit expression and had a c-Kit hi L-GMP population comparable to that of Ink4a-Arf À/À iGMPs (Figure 4d) . None of these findings in vitro revealed any apparent differences between Ink4a-Arf À/À and Bmi1 À/À Ink4a-Arf À/À /Bmi1 iGMPs. We next examined the leukemogenic activity of Bmi1 À/À Ink4a-Arf À/À /Bmi1 iGMPs in vivo. To our surprise, however, the complementation of Ink4a-Arf À/À /Bmi1 iGMPs with Bmi1 did not restore their leukemogenic activity (Figure 4e ). Mice infused with Bmi1
iGMPs developed leukemia with a latency comparable to that of Bmi1 À/À Ink4a-Arf À/À iGMPs.
Bmi1 is essential for faithful leukemic reprogramming
Neither deletion of Ink4a and Arf nor complementation by exogenous Bmi1 could restore the full leukemogenic activity of Bmi1 À/À iGMPs. These findings prompted us to hypothesize that the transcriptional reprogramming by MLL-AF9 differed in the absence of Bmi1. To test this notion, we purified the c-Kit
Ink4a-Arf À/À and Bmi1 À/À Ink4a-Arf À/À /Bmi1 iGMPs and analyzed its gene expression profile. As expected, the expression of many genes was altered. We selected genes exhibiting a X2-fold change in Bmi1 À/À Ink4a-Arf À/À iGMPs compared with control Ink4a-Arf À/À iGMPs. As a result, we identified 70 upregulated genes and 103 downregulated genes in total (Figures 5a, Supplementary Table S1) . Notably, the complementation of Bmi1 À/À Ink4a-Arf À/À iGMPs with Bmi1 did not restore the expression of the majority of genes with deregulated expression. Only 8 of the 70 upregulated genes and 20 of the 103 downregulated genes were restored to a level of expression comparable to that in Ink4a-Arf À/À iGMPs, and 9 downregulated genes were expressed at levels higher than those in Ink4a-Arf Table S1 ). By contrast, targets of MLL-AF9, including a series of Hox family genes, Meis1 and Mef2c, were expressed in Bmi1 À/À Ink4a-Arf À/À iGMPs at levels comparable to those in Ink4a-Arf À/À iGMPs (Figure 5b ). The expression of stemness-related genes and genes for cytokine receptors, myeloid specific proteins and myeloid transcription factors was not profoundly altered in Bmi1 Figure S1) . Among genes, the expression of which was deregulated in the absence of Bmi1, de-repressed genes are potential direct targets of Bmi1 because Bmi1 functions as a transcriptional repressor. Given that the loss of Bmi1 affected leukemogenic activity of MLL-AF9 even in the absence of Ink4a and Arf, there seemed to be additional tumor suppressor genes regulated by Bmi1 like Ink4a and Arf. We then tested this possibility using one of the upregulated genes, Tbx15 (Figure 5b ). Tbx15 is a member of the T-box family of transcription factors, which are required for early cell-fate decisions, differentiation and organogenesis. 19 However, nothing is known about its function in hematopoiesis or leukemia. Tbx15 was expressed specifically in common myeloid progenitors during normal myeloid differentiation but not in GMPs (data not shown). As demonstrated by microarray analyses, Tbx15 expression was highly derepressed in Bmi1 À/À and Bmi1 À/À Ink4a-Arf À/À iGMPs (Figure 6a ). The complementation of Bmi1 À/À Ink4a-Arf À/À iGMPs with Bmi1 did not restore its expression level (Figure 6a ). We then overexpressed Tbx15 in Ink4a-Arf À/À iGMPs and performed replating assays. Ink4a-Arf À/À iGMPs expressing Tbx15 showed a reduction in replating efficiency (Figure 6b ) and formed disperse colonies along with compact colonies (Figure 6c ). Ink4a-Arf À/À iGMPs expressing Tbx15 behaved like Bmi1 À/À Ink4a-Arf À/À iGMPs in these in vitro assays (Figures 6b and c) . Finally, chromatin immunoprecipitation (ChIP) assays confirmed the binding of Bmi1 to the Tbx15 promoter (Figures 6d). The Tbx15 promoter was also marked with PRC1-mediated histone modifications, monoubiquitination of histone H2A (H2Aub1) at lysine 119 (Figure 6d ). These results indicate that Bmi1 directly represses the expression of Tbx15. Consistent with the mRNA expression data, however, the complementation of Bmi1 À/À Ink4a-Arf À/À iGMPs with Bmi1 did not restore the binding of Bmi1 to the Tbx15 promoter or the level of H2AK119ub1 (Figure 6d ). 20 Likewise, repression of BMI1 in human AML CD34 þ cells impaired their self-renewal capacity in culture. 21 All these findings underscore an important role for BMI1 in the maintenance and/or augmentation of tumorigenic capacity of the established CSCs. Leukemic transformation is a process of epigenetic reprogramming, which accompanies drastic changes in the gene expression profile of cells of origin, and thought to involve epigenetic regulators, including PcG proteins. In this study, we examined the role of Bmi1 in leukemic reprogramming by directly targeting Bmi1 À/À GMPs with MLL-AF9. In contrast to Bmi1 À/À GMPs, the proliferative capacity of which was profoundly restored by deletion of Ink4a-Arf, the defective leukemogenic capacity of Bmi1 À/À iGMPs was only partially restored by deletion of Ink4a-Arf, indicating that Bmi1 regulates additional gene loci to confer full leukemogenic activity on LSCs. Of interest, we found that the major targets of MLL-AF9 were transcriptionally activated and GMPs were transformed in vitro even in the absence of Bmi1, whereas a large number of stemness-related genes were insufficiently activated in Bmi1 À/À LSCs. Moreover, many genes were deregulated in their expression in Bmi1 À/À LSCs. Among these, derepressed genes were speculated to be potential direct targets of Bmi1 and the downregulation of other genes to be indirect effects of derepressed genes. Derepressed genes included Tbx15, which seemed to be a potential tumor suppressor gene. Bmi1 has a crucial role in transcriptional repression of both tumor suppressor genes and developmental regulator genes in HSCs. 4, 6 This might be true in LSCs, in which BMI1 expression is often upregulated. Improper reprogramming of myeloid progenitor cells, such as insufficient activation of stemness-related genes and a failure in the silencing of tumor suppressor genes, could account for the impaired leukemogenic activity and differentiation tendency of Bmi1 À/À LSCs. Thus, our findings clearly demonstrated that Bmi1 regulates a cohort of genes, which are crucial for the leukemic process in addition to the classical targets, Ink4a and Arf.
In sharp contrast with HSCs, the self-renewal capacity of which was largely restored by exogenous Bmi1, complementation of Bmi1 À/À Ink4a-Arf À/À iGMPs with Bmi1 only restored in vitro phenotypes of Bmi1 À/À Ink4a-Arf À/À iGMPs, such as replating efficiency, colony morphology and the L-GMP population, but not their leukemogenic activity in vivo. Gene expression profiling revealed that the expression of the majority of deregulated genes was not restored by Bmi1. The epigenetic regulation of gene expression is a dynamic process involving multiple regulators. Once epigenetic reprogramming started in the absence of Bmi1, the epigenetic nature of Bmi1 À/À LSCs could be stabilized by other epigenetic regulators in a state different from that of ordinary leukemic reprogramming.
The Ink4a-Arf locus is the most critical target for Bmi1 in HSCs because its deletion largely restored the self-renewal capacity of Bmi1 À/À HSCs. 6 On the other hand, deletion of Ink4a-Arf only partially rescued impaired the leukemogenic activity of Bmi1 À/À Ink4a-Arf À/À iGMPs. Actually, the INK4A and ARF genes are frequently inactivated by genetic (deletions and point mutations) and epigenetic (promoter methylation) alterations in humans, 23 but BMI1 is still required for tumorigenic capacity. 20, 22 All these findings underscore the involvement of targets of Bmi1 other than Ink4a/Arf in cancer. Several studies have been carried out on this issue in different cancertypes, such as glioma, medulloblastoma and sarcoma. [24] [25] [26] Our findings have added a new set of potential target genes to the list. 
